No user fee needed for extina

Connetics Corp. has received notifications from the FDA that no user fee is required for the new drug application seeking marketing clearance for Extina (ketoconazole 2 percent) Foam. Previously, Connects announced positive results from its Phase III clinical trial with Extina versus Nizoral.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.